Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics ( SMMT -2.71%). The drugmaker's shares are up by nearly 540%, thanks to excellent clinical ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

4Q23 results included charges related to the Daiichi Sankyo collaboration .

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

In addition, efti in combination with KEYTRUDA continues to be well-tolerated with no new ... treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC).

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

Merck's Keytruda generates over $20 billion in sales ... True, one of its most important indications is in non-small cell lung cancer (NSCLC), and it is in this market that ivonescimab, a ...